ASCO: Endocrine Tx Noninferior for HR+, HER2− Breast Cancer

Similar efficacy for endocrine, chemoendocrine tx for women with midrange 21-gene recurrence score.
Similar efficacy for endocrine, chemoendocrine tx for women with midrange 21-gene recurrence score.

HealthDay News — For women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer with a midrange 21-gene recurrence score, adjuvant endocrine therapy is noninferior to chemoendocrine therapy, according to a study published online June 3 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Joseph A. Sparano, MD, from the Montefiore Medical Center in Bronx, NY, and colleagues randomized 69% of 9,719 eligible women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer with a midrange recurrence score of 11 to 25 to either chemoendocrine therapy or endocrine therapy alone. 

Related Articles

The researchers found that in the analysis of invasive disease-free survival, endocrine therapy was noninferior to chemoendocrine therapy (hazard ratio for invasive disease recurrence, second primary cancer, or death, 1.08; 95% confidence interval, 0.94 to 1.24; P=.26). Similar rates of invasive disease-free survival (83.3 and 84.3 in the endocrine-therapy group and chemoendocrine therapy group, respectively), freedom from disease recurrence at a distant site (94.5 and 95.0%), or at a distant or local-regional site (92.2 and 92.9%), and overall survival (93.9 and 93.8%) were seen in the 2 treatment groups at 9 years.

"Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score," the authors write.

Several authors disclosed financial ties to Genomic Health, which partially funded the study; 1 author holds a patent issued and licensed to Genomic Health.

Abstract/Full Text
More Information